References

The changing face of rheumatoid arthritis therapy: results of serial surveys

10.1002/1529-0131(200002)43:2<464::aid-anr30>3.0.co;2-u · 2000 · External reference

6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease

10.1097/00042737-200012110-00010 · 2000 · External reference

Methotrexate in the treatment of arthritis and connective tissue diseases

10.3949/ccjm.54.4.327 · 1987 · External reference

Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation

2006 · External reference

Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?

10.1046/j.1365-2036.2004.01819.x · 2004 · External reference

Methotrexate and histologic hepatic abnormalities: a meta-analysis

10.1016/s0002-9343(05)80060-9 · 1991 · External reference

Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy

10.2340/0001555572361364 · 1992 · External reference

Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study

10.1016/j.jhep.2010.04.043 · 2010 · External reference

Associated factors with liver fibrosis in rheumatoid arthritis patients treated with methotrexate

10.1007/s10067-023-06847-7 · 2024 · External reference

Risk of liver fibrosis in methotrexate-treated patients: a systematic review

2022 · External reference

A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn’s disease receiving methotrexate therapy

2020 · External reference

Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial

10.3109/00365521.2011.647412 · 2012 · External reference

Prevalence of liver fibrosis by Fibroscan in patients on long-term methotrexate therapy for rheumatoid arthritis

10.1007/s10067-021-05678-8 · 2021 · External reference

Unresolved reference

External reference

Use of the EvalObs® adherence scale in an unselected French population of treated subjects with antihypertensive, hypolipemiants or oral antidiabetics medications: the FLAHS 2017 adherence survey

10.1016/j.ancard.2018.05.002 · 2018 · External reference

High frequency of methotrexate intolerance in longstanding rheumatoid arthritis: using the methotrexate intolerance severity score (MISS)

10.1186/s42358-020-00145-5 · 2020 · External reference

Methotrexate-induced hepatic injury in an adult. A case report

10.1001/archinte.1964.00280080027006 · 1964 · External reference

Hepatic fibrosis and Cancer: the silent threats of metabolic syndrome

10.4093/dmj.2023.0240 · 2024 · External reference

Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists

10.1136/ard.55.5.273 · 1996 · External reference

Monitoring methotrexate toxicity in juvenile idiopathic arthritis

10.3899/jrheum.090482 · 2009 · External reference

Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury

10.1046/j.1440-1746.2001.02644.x · 2001 · External reference

EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update

10.1016/j.jhep.2021.05.025 · 2021 · External reference

Noninvasive methods for assessing liver fibrosis and steatosis

2024 · External reference

Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate

10.1136/annrheumdis-2016-210629 · 2017 · External reference

Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus

2008 · External reference

Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis

10.1016/j.jhep.2009.06.008 · 2009 · External reference

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated

10.1016/j.jhep.2022.12.034 · 2023 · External reference

Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis

10.1016/j.alcohol.2004.07.008 · 2004 · External reference

The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment

10.1001/archderm.1989.01670210056007 · 1989 · External reference

Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines

10.1371/journal.pone.0194401 · 2018 · External reference

Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy

10.1093/rheumatology/kep023 · 2009 · External reference

Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial

10.1002/art.20167 · 2004 · External reference

A novel panel of blood markers to assess the degree of liver fibrosis

10.1002/hep.20935 · 2005 · External reference

Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment

10.1016/j.jhep.2007.01.024 · 2007 · External reference

Comparison of noninvasive screening tools for hepatic fibrosis, association with methotrexate cumulative dose, and risk factors in psoriasis patients

10.1111/dth.15203 · 2022 · External reference

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents

10.1016/j.jaad.2009.03.027 · 2009 · External reference